Clinical Study Updates, Financial Results, Conference Schedules, and Securities Offerings - Research Report on Novo Nordisk, The Cooper Companies, Parexel, Oculus, and Thoratec PR Newswire NEW YORK, December 10, 2013 NEW YORK, December 10, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Novo Nordisk A/S (NYSE: NVO), The Cooper Companies Inc. (NYSE: COO), PAREXEL International Corporation (NASDAQ: PRXL), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) and Thoratec Corp. (NASDAQ: THOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Novo Nordisk A/S Research Report On December 3, 2013, Novo Nordisk A/S (Novo Nordisk) announced that a new phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation. According to the Company, IDegLira is the first-ever once-daily, single administration combination of a long-acting basal insulin and glucagon-like peptide 1 (GLP-1) analogue being developed by Novo Nordisk. The Company informed that the DUAL™ II trial shows that in comparison with insulin degludec, IDegLira achieved superior control of blood sugar levels (HbA1c). Also, improved fasting and postprandial plasma glucose levels were seen with IDegLira throughout the day and across meals, while providing significant weight loss for adults with type 2 diabetes uncontrolled on basal insulin. The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s=DDD http://www.analystscorner.com/r/full_research_report/fee1_NVO -- The Cooper Companies Inc. Research Report On December 5, 2013, The Cooper Companies, Inc. (Cooper) reported its Q4 FY 2013 and full-year FY 2013 financial results (period ended October 21, 2013). During the quarter, the Company reported revenue growth of 3.9% YoY to $411.9 million, while diluted EPS declined 21.2% YoY to $1.15. For full-year FY 2013, revenues came in at $1.6 billion, representing a growth of 9.9% YoY, and diluted EPS came in at $5.96, reflecting an increase of 18.0% YoY. Commenting on the results, Robert S. Weiss, Cooper's President and CEO said, "We are proud of our many accomplishments throughout the year including CooperVision's success with its Biofinity® family of products and launch of MyDay™ along with CooperSurgical's success with its fertility franchise. As we enter fiscal 2014, we remain encouraged by our business trends and believe we are well positioned to deliver strong operating results." The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/9cde_COO -- PAREXEL International Corporation Research Report Parexel International Corp. (Parexel) posted on their events web page that the Company will be participating in the upcoming JPMorgan Healthcare Conference, to be held on January 15, 2014, Wednesday at 7:30 a.m. PT. Parexel posted that the event will be held in San Francisco, California, US. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/067b_PRXL -- Oculus Innovative Sciences, Inc. Research Report On December 4, 2013, Oculus Innovative Sciences, Inc. (Oculus) announced an offering to sell securities to select accredited investors for aggregate gross proceeds of $2.2 million. Oculus stated that it intends to use the net proceeds from the offering for working capital and general corporate purposes. The securities in the offering include 550,000 shares of Oculus common stock at a price of $4.00 per share with no warrant coverage. The Company expects the offering to close on or about December 9, 2013, subject to satisfaction of customary closing conditions. The Full Research Report on Oculus Innovative Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/a3ee_OCLS -- Thoratec Corp. Research Report Thoratec Corp. (Thoratec) posted on their events web page that the Company will be presenting at the upcoming Oppenheimer Healthcare Conference. As per the post, the presentation will be held on December 10, 2013 at 2:10 p.m. ET and will be broadcast live over the internet. The Full Research Report on Thoratec Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/1bee_THOR ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Study Updates, Financial Results, Conference Schedules, and Securities Offerings - Research Report on Novo Nordisk, The
Press spacebar to pause and continue. Press esc to stop.